中国实验血液学杂志最新文献

{"title":"[The Reduction of CD4⁺ T Lymphocytes after the Treatment of Follicular Lymphoma with the Bendamustine Containing Regimen May Predict the Occurrence of Infection and Efficacy].","authors":"Jin-Lian Li, Wan-Chuan Zhuang, Xing-Xing Chai","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.009","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.009","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effectiveness, safety, and related prognostic factors of the treatment of follicular lymphoma (FL) with a regimen containing Bendamustine.</p><p><strong>Methods: </strong>The clinical data of 129 FL patients who were treated with Bendamustine containing regimen were collected from January 1,2020 to October 30,2022 in the Hematology Department of Lianyungang Second People's Hospital and Jiangsu Provincial People's Hospital. The patients were divided into three groups: Bendamustine plus Rituximab (BR), Bendamustine plus Obinutuzumab (GB), Rituximab + Cyclophosphamide + Epirubicin / Doxorubicin + Vindesine + Prednisone (R-CHOP). The efficacy, safety and related prognostic factors of the treatment of FL with a regimen based on Bendamustine were retrospectively analyzed.</p><p><strong>Results: </strong>The ORR was 98% for the BR group, 94% for the GB group, and 72.3% for the R-CHOP group, while the CR rate was 61.2%,70% and 40.4%, respectively. The ORR and CR rates of the R-CHOP group were statistically different from those of the BR group and GB group (<i>P</i> < 0.05). The 3-year PFS rate of the BR group, GB group, and R-CHOP group was 89.6%, 90.9%, 48.9%, respectively. There was a statistically significant difference in 3-year PFS between the R-CHOP group, BR group, and GB group (<i>P</i> < 0.05), while there was no statistically significant difference in 3-year OS（<i>P</i> ＞0.05）. Hematological adverse reactions were mainly bone marrow suppression. Lymphocytes and CD4⁺T lymphocytes decreased to the lowest level about 6 months after treatment, and the incidence of lymphopenia in BR group and GB group was higher than that in R-CHOP group, with a statistical difference (<i>P</i> < 0.05). The higher incidence of non-Hematological adverse reactions were pulmonary infection, EB virus infection, hepatitis B virus reactivation, and gastrointestinal reactions without statistical difference in 3 groups (<i>P</i> >0.05), and were all controllable. The Receiver operating characteristic of CD4⁺T lymphocyte count showed that AUC of BR group was 0.802, and the critical value was 258/uL; AUC of GB group was 0.754 with a critical value of 322/uL.</p><p><strong>Conclusion: </strong>The treatment of FL with the Bendamustine containing regimen has good efficacy and controllable adverse reactions, but lymphocytopenia was significant after treatment, and the curative efficacy in combination with various CD20 monoclonal antibodies was different. The lowest CD4⁺T lymphocyte count can be used as a predictive factor for the occurrence of infection and efficacy of the Bendamustine containing regimen for FL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect of <i>TLK2</i> Expression Regulated by MiR-21 on Proliferation and Apoptosis of Acute Myeloid Leukemia Cells].","authors":"Bo Liang, Jun-Jie Yin, Sheng-Nan Zhang, Chao Zhang, Zi-Long Hu, Yi Wang","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.002","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.002","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of <i>TLK2</i> expression regulated by miR-21 on proliferation and apoptosis of acute myeloid leukemia cells.</p><p><strong>Methods: </strong>Seventy patients with AML admitted to our hospital from January 2019 to July 2022 were selected, while 30 patients with iron deficiency anemia were selected as the control group. Bone marrow mononuclear cells (BMMNCs) of the patients were obtained using Ficoll density gradient centrifugation. RT-qPCR was used to determine the expression levels of <i>miR-21</i> and <i>TLK2</i> mRNA in BMMNCs. Mimics-miR-21, mimics-NC, inhibitor-miR-21, inhibitor-NC and NC were transfected into HL-60 cells using liposome-mediated transfection technology. CCK-8 method was used to determine the activity of transfected HL-60 cells after treatment with cytarabine. The apoptosis rate of HL-60 transfected cells was determined by TUNEL method. The expression of <i>TLK2</i> mRNA in HL-60 cells transfected with inhibitor-miR-21 was determined by RT-qPCR.</p><p><strong>Results: </strong>The relative expression levels of <i>miR-21</i> and <i>TLK2</i> mRNA in BMMNCs of AML patients were significantly higher than those of controls (both <i>P</i> < 0.05). After HL-60 cells were treated with cytarabine, both the cell activity of inhibitor-miR-21 group and mimics-miR-21 group decreased significantly with the increase of cytarabine concentration (both <i>P</i> < 0.05). However, at each concentration point of cytarabine, the cell activity of inhibitor-miR-21 group was lower than that of control group (<i>P</i> < 0.05), while mimics-miR-21 group was higher than control group (<i>P</i> < 0.05). After HL-60 cells were treated with cytarabine, the apoptosis rate of inhibitor-miR-21 group was significantly increased (<i>P</i> < 0.05), while that of mimics-miR-21 group was significantly decreased (<i>P</i> < 0.05). After HL-60 cells were treated with inhibitor-miR-21, the relative expression of <i>TLK2</i> mRNA decreased significantly (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>miR-21 is highly expressed in AML patients, which may promote the apoptosis of AML cells by inhibiting the expression of <i>TLK2</i>.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Identification Idea of Antibodies Against Ku and Other High-Frequency Antigens].","authors":"Fei-Fei Zhang, Jing-Wei Li, Wei Shen, Yi He, Hong Yuan, Li Tian, Zhi-Jun Ye","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.035","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.035","url":null,"abstract":"<p><strong>Objective: </strong>This study was aimed to provide ideas for identifying the antibodies to high-frequency antigens by analyzing a female case of high-frequency antigen antibody (anti-Ku) using serological and sequencing method.</p><p><strong>Methods: </strong>The methods for identification of blood group, erythrocyte antigen, screening and identification of antibody were used to detect the blood type and antibody in the proband. The proband's serum and reagent screening cells treated with Sulfhydryl reagent were applied to judge the type and characteristics of this antibodies when reacted with the regaent screening cells or proband's serum respectively. Gene sequencing was used to determine the genotype of the proband's blood group.</p><p><strong>Results: </strong>The proband's red blood cells were determined as O type RhD positive, whose serum showed strong positive reaction to antibody-screening cells and antibody identification cells with the same intensity in saline and IAT medium, however, the self-cells showed negative effect. The Direct Antihuman Globulin of proband's red blood cells also showed weak positive reaction, and the other blood types were CcEe, Jk(a+b-), P1-, Le(a-b -), Lu (a-b +), K-, k-, Kp(a-b-). Serum of the proband treated with 2-ME still react with three groups of screening cells in IAT medium. The reaction intensity of proband's serum was also unchanged with the cells modified with papain and bromelain, but showed negative effect when the cells were treated with sulfhydryl agents including DTT and 2-ME. Gene sequencing revealed that the <i>KEL</i> genotype of the patient was <i>KEL*02N.24</i> . This patient had a rare K0 phenotype.</p><p><strong>Conclusion: </strong>The rare Kell-null blood group (also known as K0) were identified by serological and molecular tests in the proband who produced both IgG and IgM type of antibody to high-frequency antigen (anti-Ku). These two methods are of great significance in the identification of this rare blood group as well as the antibody to high frequency antigen.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].","authors":"Xiao-Hang Pei, Li-Na Zhang, Pan Zhou, Tong-Bao Wang, Cheng Lian, Ping Zhang, Ping-Chong Lei, Zun-Min Zhu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.021","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.021","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the value of serum free light chain (sFLC) and serum calcium ion in the diagnosis and prognosis of multiple myeloma (MM).</p><p><strong>Methods: </strong>Forty patients with MM treated in Henan Provincial People's Hospital from January 2018 to January 2022 were selected as the observation group, and 40 healthy volunteers were selected as the control group. The differences of sFLC-κ、sFLC-λ、sFLC-κ/λ, serum calcium ions, etc between the two groups were compared. Meanwhile, the differences of sFLC-κ、sFLC-λ、sFLC-κ/λ, serum calcium ions, etc in different international staging systems (ISS), chemotherapy efficacy and prognosis patients were analyzed.</p><p><strong>Results: </strong>The levels of sFLC-κ［(98.39±21.19) <i>vs</i> (12.01±4.45) mg/L］, sFLC-λ［(210.20±45.54) <i>vs</i> (14.10±5.11) mg/L］ and proportions of hypocalcemia （65% <i>vs</i> 0） in the observation group were significantly higher than those in the control group (<i>P</i> < 0.05), while sFLC-κ/ λ ratio［（0.44±0.10） <i>vs</i> (0.87±0.12)］ and serum calcium ions ［（1.98±0.46） <i>vs</i> （2.42±0.40）mmol/L］ were significantly lower than those in the control group (<i>P</i> < 0.05). The sFLC-κ, sFLC-λ, the proportion of hypocalcemia and the course of hypocalcemia in ISS stage III patients in the observation group were significantly higher than those in stage I and II patients (<i>P</i> < 0.05), while sFLC-κ/λ ratio, and serum calcium ions were significantly lower than those in stage I and II patients (<i>P</i> < 0.05). The levels of sFLC-κ ［（107.76±21.22） <i>vs</i> （94.67±20.11）mg/L］, sFLC- λ［（245.54±41.12） <i>vs</i> （205.54±50.22）mg/L］ of patients with hypocalcemia in the observation group was significantly higher than those without hypocalcemia (<i>P</i> < 0.05), while the sFLC-κ/λ ratio was significantly lower than those without hypocalcemia ［（0.42±0.04） <i>vs</i> （0.47±0.06）；<i>P</i> < 0.05］. The levels of sFLC-κ ［(107.29±20.14） <i>vs</i> （ 91.11±18.92）mg/L］, sFLC-λ［（247.98±42.26） <i>vs</i> （179.29±39.32）mg/L］ in patients with ineffective chemotherapy were significantly higher than those in patients with effective chemotherapy (<i>P</i> < 0.05), while the sFLC-κ/λ ratio was significantly lower than those in patients with effective chemotherapy ［(0.43±0.10) <i>vs</i> (0.50±0.09)；<i>P</i> < 0.05）］. The area under the ROC curve for sFLC-κ, sFLC-λ, sFLC-κ/λ predicting ineffective chemotherapy was 0.803, 0.793 and 0.699 respectively, <i>P</i> < 0.05. There was no significant difference in sFLC-κ, sFLC-λ, sFLC-κ/λ ratio, serum calcium ion, hypocalcemia ratio and hypocalcemia course between survival and death patients (<i>P</i> >0.05).</p><p><strong>Conclusion: </strong>sFLC and serum calcium are related to ISS stage of MM patients. sFLC level has a certain value to predict the curative effect of chemotherapy in MM patients. However, the prognostic values of sFLC and serum calcium are not yet confirmed for MM patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Distribution Characteristics of Rh Phenotype and Feasibility of Compatible Blood Transfusion in Pregnant and Postpartum Women].","authors":"Gui-Lin Yang, Tao Zhang, Chun-Li Li, Hong-Peng Zhang, Ying-Ying Wu, Sheng-Lan Li, Kuai Wan, Yun-Ping Yang","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.034","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.034","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the distribution characteristics of Rh phenotype in pregnant and postpartum women in Chongqing area, and to explore the clinical significance of Rh phenotype in pregnant and postpartum women and the feasibility of Rh phenotype compatible blood transfusion.</p><p><strong>Methods: </strong>The ABO blood group and Rh phenotype of 65 161 pregnant and postpartum women were detected by microcolumn gel method, and 48 122 males in the same period were taken as controls. The data were analyzed by Chi-square test.</p><p><strong>Results: </strong>There were 112 870 cases (99.64%) of RhD⁺ in 113 283 samples. In RhD⁺ cases, CCDee (48.39%) and CcDEe (32.88%) were the main phenotypes. The first case of D-- phenotype in Chongqing area was detected. 413 cases (0.36%) of RhD^- were detected, with ccdee (52.78%) and Ccdee (33.41%) as the main phenotypes. Compared with RhD^- group, RhD⁺ group showed statistically significant difference in Rh phenotype distribution (<i>P</i> < 0.01). Among 65 161 maternal samples, the positive rate of 5 antigens of Rh blood group from high to low was D > e > C > c > E, and there was no significant difference compared with male samples (<i>P</i> >0.05). There was no significant difference in the distribution of Rh phenotype between males and pregnant/postpartum women, as well as between pregnant/postpartum women with different ABO blood groups (<i>P</i> >0.05). In pregnant and postpartum women, there was no significant difference in distribution of Rh phenotype among the normal pregnancy population, the population with adverse pregnancy history, the population using human assisted reproductive technology (ART) and the population with infertility (<i>P</i> >0.05). There was no significant difference in the distribution of Rh phenotype between the 4 populations mentioned above and the inpatients in the local general Grade A hospitals and the blood donors (<i>P</i> >0.05). In RhD positive pregnant and postpartum women, the probability of finding compatible blood for CcDEe phenotype was 100%, the probability of finding compatible blood for CCDee, CcDee and CCDEe phenotypes was 45%-60%, the probability of finding compatible blood for ccDEE, ccDEe and CcDEE phenotypes was 5%-10%, and the probability of finding compatible blood for other phenotypes was lower than 0.5%. The supply of blood with CCDee and ccDEE phenotypes can meet the compatible transfusions requirements of 7 Rh phenotypes in more than 99% of patients.</p><p><strong>Conclusion: </strong>Rh phenotype detection should be carried out for pregnant and postpartum women, and it is feasible to carry out Rh phenotype-matched or compatible blood transfusion for pregnant and postpartum women who need blood transfusion.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression of <i>MiR-144/451</i> in Different Types of Anemia].","authors":"Fan Yang, Ling Ling, Ya-Yin Hou, Lan Yang, Mei Sun, Fang-Fang Wang, Duo-Nan Yu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.026","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.026","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression level and clinical correlation of <i>microRNA-144/451</i> gene cluster (<i>miR-144/451</i>) in different types of anemia.</p><p><strong>Methods: </strong>The peripheral blood of patients with aplastic anemia (AA), myelodysplastic syndrome (MDS) and diffuse large B-cell lymphoma (DLBCL) who had been diagnosed with anemia for the first time and after chemotherapy were collected. The expression levels of <i>miR-144</i> and <i>miR-451</i> were measured by RT-qPCR, and the correlation between the expression levels of <i>miR-144</i> and <i>miR-451</i> and routine laboratory indexes was analyzed by Spearman correlation analysis.</p><p><strong>Results: </strong>The expression levels of <i>miR-144</i> and <i>miR-451</i> in the peripheral blood of AA and MDS patients were significantly lower than those in normal controls (all <i>P</i> < 0.01). No statistical differences were observed in the expression level of <i>miR-144</i> in three subgroups of DLBCL patients (<i>P</i> >0.05), while the expression level of <i>miR-451</i> in peripheral blood of three subgroups of DLBCL patients were significantly higher than those in normal controls (all <i>P</i> < 0.05). Correlation analysis showed that the expression levels of <i>miR-144</i> and <i>miR-451</i> in AA patients were positively correlated with red blood cell distribution width-coefficient of variation (RDW-CV) (<i>r</i> =0.629, 0.574). There were no significant correlations between the expression levels of <i>miR-144</i> and <i>miR-451</i> and laboratory parameters in MDS and DLBCL patients.</p><p><strong>Conclusion: </strong>Different types of anemia disorders have varying levels of <i>miR-144</i> and <i>miR-451</i> expression, which is anticipated to develop into a secondary diagnostic and differential diagnostic indicator for clinical anemia diseases.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparison of the Prognostic Value of C-Reactive Protein to Albumin Ratio and Glasgow Prognostic Score in Patients with Diffuse Large B-Cell Lymphoma].","authors":"Hong-Yan Wang, Hong Deng, Mei-Jiao Huang, Liang Zhang, Tai-Ran Chen, Yu Liu, Xing-Li Zou","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.013","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.013","url":null,"abstract":"<p><strong>Objective: </strong>To compare the prognostic value of two predictive models based on C-reactive protein (CRP) and albumin (ALB), namely the CRP to ALB ratio (CAR) and the Glasgow prognostic score (GPS), in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>The data of newly diagnosed DLBCL patients admitted to our center from May 2014 to January 2022 were reviewed. A total of 111 patients who completed at least 4 cycles of R-CHOP or R-CHOP-like chemotherapy with detailed clinical, laboratory data and follow-up information were included. The receiver operating characteristic (ROC) curve was performed to evaluate the predictive value of pre-treatment CAR on disease progression and survival. Furthermore, the association between CAR and baseline clinical, laboratory characteristics of patients was evaluated, and progression-free survival (PFS) and overall survival (OS) were compared between different CAR and GPS subgroups. Finally, the univariate and multivariate COX propor-tional hazard regression models were used to analyze the factors affecting disease outcomes.</p><p><strong>Results: </strong>ROC curve showed that the area under the curve (AUC) of CAR predicting PFS and OS in DLBCL patients was 0.687 (<i>P</i> =0.002) and 0.695 (<i>P</i> =0.005), respectively, with the optimal cut-off value of 0.11 for both predicting PFS and OS. Compared with the lower CAR (<0.11) group, the higher CAR (≥0.11) group had more clinical risk factors, including age >60 years (<i>P</i> =0.025), ECOG score ≥2 (<i>P</i> =0.004), Lugano stage III-IV (<i>P</i> < 0.001), non-germinal center B-cell-like (non-GCB) subtype (<i>P</i> =0.035), elevated lactate dehydrogenase (LDH) ( <i>P</i> < 0.001), extranodal involved site >1 (<i>P</i> =0.004) and IPI score >2 (<i>P</i> < 0.001). The interim response evaluation of patients showed that the overall response rate (ORR) and complete response rate (CRR) in the lower CAR group were both significantly better than those in the higher CAR group (ORR: 96.9% <i>vs</i> 80.0%, <i>P</i> =0.035; CRR: 63.6% <i>vs</i> 32.5%, <i>P</i> =0.008). With a median follow-up of 24 months, patients with lower CAR had significantly longer median PFS and OS than those with higher CAR (median PFS: not reached <i>vs</i> 67 months, <i>P</i> =0.0026; median OS: not reached <i>vs</i> 67 months, <i>P</i> =0.002), while there was no statistical difference in PFS (<i>P</i> =0.11) and OS (<i>P</i> =0.11) in patients with GPS of 0, 1, and 2. Multivariate Cox regression analysis indicated that only sex (male) and IPI score >2 were independent risk factors for both PFS and OS.</p><p><strong>Conclusion: </strong>CAR is significantly correlated with disease progression and survival in DLBCL patients; And compared with GPS, CAR has more advantages in predicting disease outcomes in DLBCL patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Thalassemia Genotypes and HbA2 levels of Children in Wuzhou, Guangxi].","authors":"Song-Xiao Wei, Feng-Yuan Li, Ying-Ying Mai, Jian-Zhi Liang","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.027","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.027","url":null,"abstract":"<p><strong>Objective: </strong>To analyze thalassemia genotypes and distribution of children in Wuzhou Guangxi, and evaluate the diagnostic value of HbA2 in children's thalassemia screening, so as to provide scientific evidence for the prevention and control strategies of thalassemia.</p><p><strong>Methods: </strong>Four hundred and fifty-eight children suspected with thalassemia in Wuzhou were enrolled from March 2017 to June 2022. The level of HbA2 was detected using Bio-Rad VARIANT II Hb analysis system. The deletion of α-thalassemia was measured with gap-PCR assay, and the point mutation of α- and β-thalassemia was tested with DNA reverse dot blot hybridization assay. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of HbA2 for children's thalassemia.</p><p><strong>Results: </strong>A total of 304 thalassemia carriers were detected in 458 children, accounting for 66.38%. One hundred and seventy-five cases were defined to be α-thalassemia, with the main type of --^<i>SEA</i>/αα (54.86%). Thirty-six cases were defined to be intermediate α-thalassemia, with the main type of -α^3.7/--^<i>SEA</i> (9.72%). In 108 cases with β-thalassemia, <i>β</i>^{<i>CD41-42</i>}/<i>β</i>^<i>N</i> was the main type, accounting for 49.07%, followed by <i>β</i>^{<i>IVS-Ⅱ-654</i>} /<i>β</i>^<i>N</i> (14.81%). Seven cases were moderate/severe β-thalassemia (predominantly <i>β</i>^-28/<i>β</i>^-28 and <i>β</i>^{<i>CD41-42</i>}/<i>β</i>^<i>CD17</i>/). Twenty-one genotypes of α- and β-thalassemia were found in the children. There was significant difference of HbA2 level between the children with different types of thalassemia and healthy controls (all <i>P</i> < 0.001). ROC curve analysis showed that the sensitivities of HbA2 for α-thalassemia, β-thalassemia and αβ-thalassemia were 74.3%, 82.4% and 85.7%, with the optimal cut-off values of 2.60%, 3.60% and 3.70%, respectively, the specificities were 64.3%, 96.1% and 96.8%, and the area under the curve were 0.690, 0.887 and 0.916, respectively.</p><p><strong>Conclusion: </strong>The thalassemia genotypes of children in Wuzhou are diverse. It is necessary to further strengthen the prevention and control measure of thalassemia to reduce birth defects and improve birth quality.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Preventive Effect of Levofloxacin Combined with G-CSF or Only G-CSF Supportive Therapy on Infection in Autologous Hematopoietic Stem Cell Transplantation].","authors":"Xin-Wei Wang, Li-Ping Yang, Qiong Yao, Jie Zhao, Shao-Long He, Liang-Ming Ma, Jun-N Wei, Wei-Wei Tian","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.039","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.039","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role of levofloxacin combined with recombinant human granulocyte colony-stimulating factor (G-CSF) or only G-CSF supportive therapy in preventing infection in autologous hematopoietic stem cell transplantation(ASCT), and to analyze the length of hospital stay, hospitalization cost and post-transplant survival of the patients.</p><p><strong>Methods: </strong>A retrospective analysis was performed in the patients with hematological malignancies who accepted ASCT at our hospital from January 2012 to July 2022, the febrile neutropenia, the incidence of bacterial infection and the use rate of intravenous antibiotics in the levofloxacin+G-CSF group and only G-CSF support group during ASCT were observed. The length of hospital stay, total cost during hospitalization and survival after 90 days of transplantation between the two groups were compared.</p><p><strong>Results: </strong>A total of 102 cases were included in this study, including 57 cases of multiple myeloma, 36 cases of acute leukaemia, 7 cases of lymphoma, 3 cases of myelodysplastic syndrome, 1 case of light chain amyloidosis, and 1 case of POEMS syndrome. 47 patients received levofloxacin+ G-CSF antibacterial prophylaxis, and 55 patients received G-CSF supportive therapy. In the levofloxacin+ G-CSF group, 40 cases (85.11%) developed febrile neutropenia, and 13 cases (27.66%) were confirmed as bacterial infection. In the G-CSF group, 44 cases (80.00%) developed febrile neutropenia, and 16 cases (29.09%) were bacterial infection. There was no statistically significant difference in the incidence of febrile neutropenia and bacterial infection between the two groups (χ²=0.46，<i>P</i> =0.50; χ²=0.03，<i>P</i> =0.87). The use rate of intravenous antibiotics in the levofloxacin+ G-CSF group was 85.11% (40/47), which was not statistically different from 85.45% (47/55) in the G-CSF group (χ²=0.04，<i>P</i> =0.84). The detection rates of levofloxacin-resistant bacteria in the levofloxacin+ G-CSF group and G-CSF group were 8.57% (3/35) and 21.43% (6/28), respectively, with no statistical difference (χ²=0.65, <i>P</i> >0.05). The median length and median cost of hospitalization in the levofloxacin+ G-CSF group and G-CSF group were 25 d <i>vs</i> 22 d and 78 216.24 yuan <i>vs</i> 80 724.38 yuan, with no statistically significant differences ( <i>t</i> =3.00，<i>P</i> =0.09; <i>t</i> =0.94，<i>P</i> =0.09). Within 90 days after transplantation, two cases (4.26%) died in the levofloxacin+ G-CSF group and one case (1.82%) died in the G-CSF group, with no statistically significant difference between the two groups (χ²=0.53，<i>P</i> =0.47).</p><p><strong>Conclusion: </strong>Application of levofloxacin+ G-CSF showed no significant benefit compared to G-CSF support for the prevention of bacterial infections during ASCT.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy of a Daltuzumab-containing Regimen in Patients with mSMART High-Risk Multiple Myeloma].","authors":"Zhen-Lun Qi, Ya-Qin Luo, Shu-Min Ding, Zhao-Xia Liu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.018","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.018","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of a treatment regimen based on daratumumab in patients with high-risk relapsed refractory multiple myeloma(MM) with mSMART 3.0 score.</p><p><strong>Methods: </strong>Clinical data were collected from 16 patients with mSMART3.0 score high-risk relapsed refractory MM treated at the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from May 2020 to May 2023, all of whom received daltezumab-based regimen (regimen drugs including dexamethasone, isazomib, bortezomib, lenalidomide). The efficacy and safety of the treatment were retrospectively analyzed.</p><p><strong>Results: </strong>The median age of 16 patients was 63.5 (47-70) years old, including 10 cases of IgG type, 2 cases of IgA type, and 4 cases of light chain type. The curative efficacy was judged in all 16 patients, with an overall response rate of 93.75% (15/16), including 4 cases of strict complete remission (sCR), 1 case of complete remission (CR), 2 case of very good partial remission (VGPR), partial remission (PR) in 5 cases, and minor remission (MR) in 3 cases. The median follow-up time was 11(2-30) months, and the median progression-free survival and median overall survival were not achieved in 16 patients at the median follow-up period. The hematologic adverse effects of the treatment regimen using daratumumab-based were mainly neutropenia, and the non-hematologic adverse effects were mainly infusion-related adverse reactions and infections.</p><p><strong>Conclusion: </strong>Daratumumab-based regimen for the treatment of relapsed refractory MM patients with high risk of mSMART3.0 score has better efficacy and safety.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}